Page last updated: 2024-08-26

fulvestrant and pd 0325901

fulvestrant has been researched along with pd 0325901 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L1

Other Studies

1 other study(ies) available for fulvestrant and pd 0325901

ArticleYear
Exploiting MEK inhibitor-mediated activation of ERĪ± for therapeutic intervention in ER-positive ovarian carcinoma.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2013